Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 5, 2007, Pages 637-645

  Mehta, S H ^a   Lucas, G ^a,c   Astemborski, J ^a   Kirk, G D ^a,c   Vlahov, D ^b   Galai, N ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HAIFA   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; COMMUNITY CARE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OUTPATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34248572206     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701235644     Document Type: Article

References (30)

1. Arnsten, J.H., Demas, P.A., Grant, R.W., Gourevitch, M.N., Farzadegan, H., Howard, A.A., & Schoenbaum, E.E. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377-81.
2. Clarke, S. M., & Mulcahy, F.M. (2000). Antiretroviral therapy for drug users. International Journal of STD & AIDS, 11, 627-31.
3. Dronda, F., Moreno, S., Moreno, A., Casado, J.L., Perez-Elias, M.J., & Antela, A. (2002). Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clinical Infectious Diseases, 35, 1005-1009.
4. Dronda, F., Zamora, J., Moreno, S., Moreno, A., Casado, J.L., Muriel, A., Perez-Elias, M.J., Antela, A., Moreno, L, & Quereda, C. (2004). CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS, 18, 2210-12.
5. Grabar, S., Le M, V., Goujard, C., Egger, M., Leport, C., Kazatchkine, M.D., Weiss, L., & Costagliola, D. (2005). Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. Journal of Acquired Immune Deficency Syndromes, 39, 284-92.
6. Grabar, S., Le M, V., Goujard, C., Leport, C., Kazatchkine, M.D., Costagliola, D., & Weiss, L. (2000). Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Annals of Internal Medicine, 133, 401-10.
7. Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., & Telenti, A. (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 356, 1800-1805.
8. Kapadia, F., Vlahov, D., Donahoe, R.M., & Friedland, G. (2005). The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clinical Infectious Diseases, 41, 1027-34.
9. Lucas, G.M., Cheever, L.W., Chaisson, R.E., & Moore, R.D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficency Syndromes, 27, 251-59.
10. Lucas, G.M., Griswold, M., Gebo, K.A., Keruly, J., Chaisson, R.E., & Moore, R.D. (2006). Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. American Journal of Epidemiology, 163, 412-20.
11. Lucas, G.M., Weidle, P.J., Hader, S., & Moore, R.D. (2004). Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clinical Infectious Diseases, 38 Suppl 5:S409-13., S409-S413.
12. Mellors, J.W., Munoz, A., Giorgi, J.V., Margolick, J.B., Tassoni, C.J., Gupta, P., Kingsley, L.A., Todd, J.A., Saah, A.J., Detels, R, Phair, JP, & Rinaldo, CR,Jr. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 126, 946-54.
13. Mellors, J.W., Rinaldo, C.R.Jr., Gupta, P., White, R.M., Todd, J.A., & Kingsley, L.A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-70.
14. Mocroft, A., Madge, S., Johnson, A.M., Lazzarin, A., Clumeck, N., Goebel, F. D., Viard, J.P., Gatell, J., Blaxhult, A., & Lundgren, J.D. (1999). A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Journal of Acquired Immune Deficency Syndromes, 22, 369-78.
15. Mocroft, A., Vella, S., Benfield, T.L., Chiesi, A., Miller, V., Gargalianos, P., d'Arminio, M.A., Yust, I., Bruun, J.N., Phillips, A.N., & Lundgren, J.D. (1998). Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet, 352, 1725-30.
16. Moore, D.M., Hogg, R.S., Yip, B., Wood, E., Tyndall, M., Braitstein, P., & Montaner, J.S. (2005). Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. Journal of Acquired Immune Deficency Syndromes, 40, 288-93.
17. Nicastri, E., Chiesi, A., Angeletti, C., Sarmati, L., Palmisano, L., Geraci, A., Andreoni, M., & Vella, S. (2005). Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. Journal of Medical Virology, 76, 153-60.
18. Palella, F.J.,Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., & Holmberg, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-60.
19. Palepu, A., Tyndall, M., Yip, B., O'Shaughnessy, M.V., Hogg, R.S., & Montaner, J.S. (2003). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficency Syndromes, 32, 522-26.
20. Piketty, C., Weiss, L., Thomas, F., Mohamed, A.S., Belec, L., & Kazatchkine, M.D. (2001). Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. Journal of Infectious Diseases, 183, 1328-35.
21. Pontali, E. (2005). Antiretroviral treatment in correctional facilities. HIV Clinical Trials, 6, 25-37.
22. Rich, J.D., Holmes, L., Salas, C., Macalino, G., Davis, D., Ryczek, J., & Flanigan, T. (2001). Successful linkage of medical care and community services for HIV-positive offenders being released from prison. Journal of Urban Health, 78, 279-89.
23. Roca, B., Gomez, C.J., & Arnedo, A. (1999). Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. Journal of Infection, 39, 141-45.
24. Rosen, D.L., Golin, C.E., Schoenbach, V.J., Stephenson, B.L., Wohl, D.A., Gurkin, B., & Kaplan, A.H. (2004). Availability of and access to medical services among HIV-infected inmates incarcerated in North Carolina county jails. Journal of Health Care for the Poor and Underserved, 15, 413-25.
25. Springer, S.A., Pesanti, E., Hodges, J., Macura, T., Doros, G., & Altice, F.L. (2004). Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases, 38, 1754-60.
26. Vlahov, D., Anthony, J.C., Munoz, A, Margolick, J, Nelson, KE, Celentano, DD, Solomon, L, & Polk, BF. (1991). The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Research Monograph, 109, 75-100.
27. Vlahov, D., Galai, N., Safaeian, M., Galea, S., Kirk, G.D., Lucas, G.M., & Sterling, T.R. (2005). Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. American Journal of Epidemiology, 161, 999-1012.
28. Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J.G., Margolick, J.B., Lyles, C.M., Nelson, K.E., Smith, D., Holmberg, S., & Farzadegan, H. (1998). Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. Journal of the American Medical Association, 279, 35-40.
29. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., & Hogg, R.S. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169, 656-61.
30. Zaccarelli, M., Barracchini, A., De Longis, P., Perno, C.F., Soldani, F., Liuzzi, G., Serraino, D., Ippolito, G., & Antinori, A. (2002). Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care & STDS, 16, 67-73.